Ascendis increases expenses shortly before moment of truth
The US FDA will announce its decision on Ascendis Pharma's first drug on June 25 at the latest, and the firm is getting everything ready for a possible launch.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The last month of Ascendis' second quarter will be eventful for the Danish biotech company listed in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin gets ready for launch in second half-year of 2021
For subscribers
Leo Pharma's board now has one person less
For subscribers
Ascendis powers ahead on capital spending
For subscribers
.jpg&w=384&q=75)
